Bactericidal Permeability Increasing Protein: A Potent Naturally Occurring Anti-Endotoxin Protein

  • C. J. Fisher
  • S. M. Opal
  • M. N. Marra
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 16)


Sepsis syndrome is the systemic inflammatory response associated with severe infection, bacteremia, and/or endotoxemia and is a leading cause of morbidity and mortality among hospitalized patients despite the use of potent antibiotics and intensive support procedures. Approximately 400, 000 to 500, 000 cases are reported each year in the United States, and the incidence is increasing. In the ten year period ending 1987, the discharge diagnosis of sepsis syndrome had increased by 139% with an average mortality of 40 to 45% [1–5]. The systemic inflammatory response is generally initiated by an exogenous challenge from bacterial toxins stimulating release of endogenous mediators such as tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, bradykinin, and other important pro-inflammatory mediators [5–11]. Both gram-positive and gram-negative bacteria produce sepsis syndrome [1]. In approximately 60% of cases with a known etiology, sepsis is associated with gram-negative bacteria.


Sepsis Syndrome Azurophil Granule Endotoxin Challenge Bactericidal Permeability Increase Human Poly 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bone RC, Fisher CJ Jr, Clemmer TP, et al. (1989) Sepsis Syndrome: A valid clinical entity. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC, Fisher CJ Jr, Clemmer TP, et al. (1987) A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRefGoogle Scholar
  3. 3.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Eng J Med 324:429–436CrossRefGoogle Scholar
  4. 4.
    Incrase in national hospital discharge survey rates for septicemia — United States, 1979-1987 (1990) MMWR 39:31–34Google Scholar
  5. 5.
    Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355PubMedCrossRefGoogle Scholar
  6. 6.
    Michie HR, Manogue KR, Spriggs DR, et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486PubMedCrossRefGoogle Scholar
  7. 7.
    Calandra T, Glauser MP (1990) Cytokines and septic shock. Diagn Microbiol Infect Dis 13:377–381PubMedCrossRefGoogle Scholar
  8. 8.
    Calandra T, Gerain J, Heumann D, et al. (1991) High circulating levels of interleukin-6 in pa-, tients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 91:23–29PubMedCrossRefGoogle Scholar
  9. 9.
    Calandra T, Baumgartner JD, Grau GE, et al. (1990) Prognostic values of tumor necrosis fac-tor/cachectin, interleukin-1, interferon-a and interferon-γ in the serum of patients with septic shock. J Infec Dis 161:982–987CrossRefGoogle Scholar
  10. 10.
    Okusawa S, Gelfand JA, Ikejima T, et al. (1988) Interleukin-1 induces a shock-like state in rabbits synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. Clin Invest 81:1162–1172CrossRefGoogle Scholar
  11. 11.
    Morrison DC (1987) Endotoxin and desease mechanism. Ann Rev Med 38:417PubMedCrossRefGoogle Scholar
  12. 12.
    McCabe WR, DeMaria A Jr, Berberich H, et al. (1988) Immunization with rough mutants of Salmonella Minnesota: Protective activity of IgM and IgG antibody to the R 595 (Re chemo-type) mutant. J Infect Dis 158:291–300PubMedCrossRefGoogle Scholar
  13. 13.
    Ziegler EJ, Teng NNH, Douglas H, et al. (1987) Treatment of Pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E. coli, lipid-A. Clin Res 35:619AGoogle Scholar
  14. 14.
    Ziegler EJ, McCutchan JA, Fierer J, et al. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant E. coli. N Engl J Med 307:1225–1230PubMedCrossRefGoogle Scholar
  15. 15.
    Baumgartner JD, Glauser MP, McCutchan JA, et al. (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59–63PubMedCrossRefGoogle Scholar
  16. 16.
    Greenman RL, Schein RMH, Martin, et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102PubMedCrossRefGoogle Scholar
  17. 17.
    Fearon DT, Wong WW (1983) Complement ligand-receptor interactions that mediate biological responses. Ann Rev Immunol 1:243CrossRefGoogle Scholar
  18. 18.
    Berger J, O’Shea JO, Cross NS, et al. (1984) Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest 74:1566PubMedCrossRefGoogle Scholar
  19. 19.
    Davis CF, Moore FD, Rodrick ML, Fearon DT (1987) Neutrophil activation after burn injury: Contributions of the classic complement pathway and of endotoxin. Surgery 102:477PubMedGoogle Scholar
  20. 20.
    Moore FD, Moss NA, Revhaug D, et al. (1987) A single dose of endotoxin activated neutrophils without activating complement. Surgery 102:200PubMedGoogle Scholar
  21. 21.
    Ganz T, Selsted ME, Szklarek D, et al. (1985) Defensins: Natural peptide antibiotics of human neutrophils. J Clin Invest 76:1427PubMedCrossRefGoogle Scholar
  22. 22.
    Wilde CG, Griffith JE, Marra MN, et al. (1989) Purification and characterization of HPN-4. A novel member of the Defensin family. J Biol Chem 264:11200PubMedGoogle Scholar
  23. 23.
    Biondin J, Janoff A (1976) The role of lysosomal elastase in the digestion of E. coli proteins by human polymorphonuclear leukocytes. J Clin Invest 58:971CrossRefGoogle Scholar
  24. 24.
    Gabay JE, Scott RW, Campanelli S, et al. (1989) Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 86:5610PubMedCrossRefGoogle Scholar
  25. 25.
    Houde CJ, Gray BH (1986) Physiologic effects of a bactericidal protein from human polymorphonuclear leukocytes on pseudomonas aeruginosa. Infect Immun 52:90Google Scholar
  26. 26.
    Weiss J, Elsbach P, Olsson I, Odegerg H (1978) Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 253:2664PubMedGoogle Scholar
  27. 27.
    Weiss J, Muello K, Victor M, Elsbach P (1984) The role of lipopolysaccharide in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 132:3109PubMedGoogle Scholar
  28. 28.
    Manion BA, Weiss J, Elsbach P (1990) Separation of sublethal and lethal effects of polymorphonuclear leukocytes on E. coli. J Clin Invest 85:853CrossRefGoogle Scholar
  29. 29.
    Marra MN, Wilde CG, Griffith JE, et al. (1990) Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 144:662–666PubMedGoogle Scholar
  30. 30.
    Opal SM, Fisher CJ, Marra MN, Scott RW, Palardy JE (1991) Bactericidal/permeability-increasing protein is a novel therapeutic modality in the treatment of endotoxic shick. Clin Res 39:351Google Scholar
  31. 31.
    Tobias PS, Matison JC, Ulevitch RJ (1988) A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem 263:13479PubMedGoogle Scholar
  32. 32.
    Schuman RR, Leong SR, Flaggs GW, et al. (1990) Structure and function of lipopolysaccha-, ride binding protein. Science 249:1429CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • C. J. Fisher
  • S. M. Opal
  • M. N. Marra

There are no affiliations available

Personalised recommendations